Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
Dated clinical, regulatory and corporate events for Merck KGaA
How MKGAF actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-10 | Pimjetmi (pimicotinib) | PDUFA Date Approved | PDUFA |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Enpatoran Small MoleculesNCT07355218 | Systematic Lupus Erythematosus | Phase 3 | RECRUITING | 202 | May 25, 2029 | ||||||
| M5049 low dose Small MoleculesNCT05540327 | Systemic Lupus Erythematosus | Phase 2 | ACTIVE NOT_RECRUITING | 406 | Aug 12, 2028 | ||||||
| Precemtabart tocentecan Antibody-Drug Conjugates (ADCs)NCT07549412 | Metastatic Colorectal Cancer | Phase 3 | RECRUITING | 1,020 | Oct 16, 2029 | ||||||
| M9140 Small MoleculesNCT06710132 | Solid Tumors | Phase 1/2 | ACTIVE NOT_RECRUITING | 196 | Dec 23, 2027 | ||||||
| M9140 Small MoleculesNCT05464030 | Colorectal Cancer | Phase 1 | ACTIVE NOT_RECRUITING | 220 | Oct 23, 2026 | ||||||
| M5542 BiologicsNCT07932795 | Eczema | Phase 1 | NOT YET_RECRUITING | 56 | Aug 14, 2028 | ||||||
| M7437 Small MoleculesNCT07360314 | Advanced Solid Tumors | Phase 1 | RECRUITING | 138 | Mar 28, 2029 | ||||||
| M3554 Small MoleculesNCT06641908 | Advanced Solid Tumor | Phase 1 | RECRUITING | 65 | Apr 16, 2027 | ||||||
| M9466 Small MoleculesNCT06421935 | Advanced Solid Tumor | Phase 1 | ACTIVE NOT_RECRUITING | 60 | Feb 22, 2027 | ||||||
| Cladribine Small MoleculesMarketedNCT04695080 | Advanced Multiple Sclerosis | Approved | ACTIVE NOT_RECRUITING | 204 | Dec 31, 2027 | ||||||
| Cladribine Small MoleculesNCT06463587 | Generalized Myasthenia Gravis | Phase 3 | RECRUITING | 264 | Nov 12, 2030 | ||||||
| Mirdametinib Small MoleculesNCT07840612 | Undisclosed | Phase 1 | RECRUITING | 17 | Nov 17, 2026 | ||||||
| Pimicotinib Small MoleculesNCT07499362 | Tenosynovial Giant Cell Tumor | Phase 2 | RECRUITING | 20 | Aug 22, 2028 | ||||||
| Avelumab BiologicsMarketedNCT03815643 | Solid Tumor | Approved | ACTIVE NOT_RECRUITING | 2,029 | Nov 24, 2026 | ||||||
| Test: Follitropin alfa Small MoleculesMarketedNCT07340827 | Infertility | Approved | RECRUITING | 266 | Sep 30, 2027 | ||||||
| Bintrafusp alfa Small MoleculesCompletedNCT05061823 | Lung Cancer | Phase 3 | COMPLETED | 22 | Mar 21, 2025 | ||||||
| M7824 Small MoleculesCompletedNCT03833661 | Biliary Tract Cancer | Phase 2 | COMPLETED | 159 | Sep 30, 2022 | ||||||
| Bintrafusp alfa Small MoleculesCompletedNCT04246489 | Uterine Cervical Neoplasms | Phase 2 | COMPLETED | 146 | Dec 14, 2022 | ||||||
| M7824 Small MoleculesCompletedNCT03840915 | Carcinoma, Non-Small-Cell Lung | Phase 1/2 | COMPLETED | 70 | Jul 29, 2022 | ||||||
| M7824 Small MoleculesCompletedNCT04551950 | Cervical Cancer | Phase 1 | COMPLETED | 25 | Jun 30, 2022 | ||||||
| MSB0011359C Small MoleculesCompletedNCT02699515 | Solid Tumors | Phase 1 | COMPLETED | 714 | Feb 21, 2022 | ||||||
| Enpatoran Small MoleculesNCT05162586 | Systemic Lupus Erythematosus | Phase 3 | COMPLETED | 1,062 | Nov 20, 2024 | ||||||
| Enpatoran Small MoleculesCompletedNCT06589713 | Renal Impairment | Phase 1 | COMPLETED | 34 | Apr 13, 2026 | ||||||
| cetuximab BiologicsCompletedNCT02383966 | Carcinoma, Squamous Cell of Head and Neck | Phase 3 | COMPLETED | 243 | Dec 20, 2021 | ||||||
| Tuvusertib Small MoleculesCompletedNCT06433219 | Ovarian Cancer | Phase 2 | COMPLETED | 63 | Aug 11, 2026 |
Readouts, endpoints and source filings for every MKGAF program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in MKGAF for Q3 2026. | ||||
Shares sold short, counted twice a month.
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
How MKGAF ranks across every disease it competes in